- 1 Title: Associations of Adipokine Levels with Levels of Remnant Cholesterol: the Multi-Ethnic
- 2 Study of Atherosclerosis (MESA)
- 3 Short Title: Adipokines and Remnant Cholesterol
- 4 Authors: Renato Quispe, MD MHS¹, Ty Sweeney, MD¹, Seth S. Martin MD, MHS¹, Steven R.
- 5 Jones MD¹, Matthew A. Allison, MD, MPH,² Matthew J. Budoff, MD³, Chiadi E. Ndumele,
- 6 MD, PhD¹, Mohamed B. Elshazly, MD⁴, Erin D. Michos, MD, MHS¹

7

8 Affiliations:

- 9 1. Ciccarone Center for the Prevention of Cardiovascular Disease, Johns Hopkins University
- 10 School of Medicine, Baltimore, MD
- 11 2. Department of Family Medicine, University of California San Diego, San Diego, CA
- 12 3. Lundquist Institute, Los Angeles, CA
- 13 4. Department of Cardiovascular Medicine, Heart and Vascular Institute, Cleveland Clinic,
- 14 Cleveland, OH

15 Word count

- **16 Abstract:** 250 (limit 250)
- 17 Main text: 3247
- **18 References:** 56
- **19 Tables: 5; Figures: 3**
- 20 Supplemental Tables: 2
- 21
- 22 Corresponding author
- 23 Erin D. Michos, MD, MHS, FACC, FAHA, FASE, FASPC

- 24 Associate Professor of Medicine
- 25 Division of Cardiology
- 26 Johns Hopkins University School of Medicine
- 27 Blalock 524-B, 600 N. Wolfe Street, Baltimore, MD, 21287
- 28 Phone: 410-502-6813; Email: edonnell@jhmi.edu; Twitter: @ErinMichos

29

31 <u>ABSTRACT</u>

32 Background

- 33 The metabolic syndrome phenotype of individuals with obesity is characterized by elevated
- 34 levels of triglyceride (TG)-rich lipoproteins and remnant particles, which have been shown to be
- 35 significantly atherogenic. Understanding the association between adipokines, endogenous
- 36 hormones produced by adipose tissue, and remnant cholesterol (RC) would give insight into the
- 37 link between obesity and atherosclerotic cardiovascular disease.
- 38

39 Methods

- 40 We studied 1,791 MESA participants of an ancillary study on body composition who had
- 41 adipokine levels measured (leptin, adiponectin, resistin) at either visit 2 or 3. RC was calculated
- 42 as non-high density lipoprotein cholesterol minus low-density lipoprotein cholesterol (LDL-C),
- 43 measured at the same visit as the adipokines, as well as subsequent visits 4 through 6.
- 44 Multivariable-adjusted linear mixed effects models were used to assess the cross-sectional and
- 45 longitudinal associations between adipokines and levels of RC.
- 46

47 Results

- 48 Mean (SD) age was 64.5±9.6 years and for body mass index (BMI) was 29.9±5.0 kg/m2; 52.0%
- 49 were women. In fully adjusted models that included BMI, LDL-C and lipid-lowering therapy, for
- 50 each 1-unit increment in adiponectin, there was 14.4% (12.0, 16.8) lower RC. With each 1-unit
- 51 increment in leptin and resistin, there was 4.5% (2.3, 6.6) and 5.1% (1.2, 9.2) higher RC,
- 52 respectively. Lower adiponectin and higher leptin were also associated with longitudinal
- 53 increases in RC levels over median follow-up of 5(4-8) years.

54 55 **Conclusions**

- 56 Lower adiponectin and higher leptin levels were independently associated with higher levels of
- 57 RC at baseline and longitudinal RC increase, even after accounting for BMI and LDL-C.
- 58
- 59 Keywords: adipokines, remnant cholesterol, obesity

61 CLINICAL PERSPECTIVE

~	2
ь	Z

63 What is new?

64

- 65 Among individuals without history of cardiovascular disease, adiponectin is inversely
- 66 associated with cross-sectional levels of remnant cholesterol, whereas leptin and resistin are
- 67 directly associated.
- 68 Adiponectin had an inverse association with progression of remnant cholesterol levels over

69 time.

70

71 What are the clinical implications?

- 72 Adiponectin levels were not associated with LDL-C levels but with levels of triglyceride-rich
- 73 lipoproteins, particularly remnant cholesterol.
- 74 -Incrementing adiponectin via lifestyle modification and/or pharmacological therapies (i.e. GLP-
- 75 1 agonists) could be a mechanism to reduce remnant cholesterol levels and ultimately
- 76 cardiovascular risk.

78 INTRODUCTION

79	Obesity is one of the most important risk factors for development of atherosclerotic
80	cardiovascular disease (ASCVD) ¹⁻³ and it is projected that 1 in 2 U.S. adults will be classified as
81	having obesity (defined by a body mass index (BMI) \ge 30 kg/m ²) by 2030. ⁴ The
82	pathophysiologic link between obesity and ASCVD is not fully understood. ⁵ In this regard, the
83	metabolic syndrome lipid phenotype of individuals with obesity is often characterized by
84	elevation of triglyceride (TG) levels and low levels of high density lipoprotein cholesterol (HDL-
85	C). ⁶
86	Mounting evidence from the last decade has shown the role of TG and TG-rich
87	lipoproteins (TGRL) in the development of ASCVD.7 Remnant lipoprotein particles (RLPs) are
88	partially lipolysed lipoproteins derived from TGRL of both liver [very low-density lipoprotein,
89	(VLDL)] and intestinal (chylomicron) origins,8 which have been shown to contribute to
90	atherosclerosis independent of, and additional to, low-density lipoprotein cholesterol (LDL-C).9,
91	¹⁰ These remnant particles contain a large amount of cholesterol and contribute to endothelial
92	dysfunction, inflammation and ultimately atherogenesis. ^{7, 11} Interestingly, elevated levels of
93	remnant cholesterol are strongly associated with higher ratios of TG to HDL-C, ¹² which are often
94	encountered among individuals with obesity and metabolic syndrome. The association between
95	remnant cholesterol (RC) and ASCVD has been established by genetic ^{13, 14} as well as
96	observational studies. ^{15, 16}
97	Adipokines, such as leptin, adiponectin and resistin, are endogenous hormones that are
98	released from adipose tissue or adjacent inflammatory cells and have been shown to influence
99	several metabolic processes such as insulin sensitivity, endothelial function and appetite

100 regulation.¹⁷⁻²¹ However, the association of adipokines with levels of RC has not been fully

elucidated, as well as the role of different adipokines in the prediction of change in RC levels. In
the analysis described below, we evaluated the associations between endogenous adipokines and
1) cross-sectional levels of RC; and 2) progression of RC levels over time.

104

105 METHODS

106 Study population

The Multi-Ethnic Study of Atherosclerosis (MESA) cohort enrolled 6,814 men and women 107 108 aged 45 to 84 years who were free of CVD at baseline (2000-2002). Adipokine levels and the 109 computed tomography (CT) assessment of visceral and subcutaneous adipose tissue (VAT and 110 SAT) were measured as part of an ancillary study in 1,970 men and women at either visit 2 or visit 111 3 (randomly assigned). The baseline for this analysis was the time of the adipokine measurement 112 (either visit 2 or 3). We included all MESA participants who had endogenous adipokines (leptin, 113 adiponectin, resistin) and a standard lipid panel obtained at either visit 2 or 3. For the primary 114 cross-sectional analysis, we used the lipid panel that was at the same visit as the adipokine 115 measurements, but for longitudinal analysis, we also used lipid panels from subsequent visits. 116 Individuals with missing data on the exposure variables, the outcome variables, or the covariates in our model were excluded (n=179), leaving a primary analytical sample of 1,791 individuals. 117

118 Independent variables assessment

119 The primary independent variables were levels of the endogenous adipokines (leptin, 120 adiponectin, and resistin) and their ratios (leptin/adiponectin and resistin/adiponectin). Samples of 121 fasting serum were obtained at either visit 2 (2002-2004) or visit 3 (2004-2005), at the visit of the 122 abdominal CT scan,²²⁻²⁴ and immediately frozen at -70°C. In 2009, the adipokines (adiponectin, 123 leptin, and resistin) were measured from these stored serum samples using a Bio-Rad Luminex

flow cytometry (Millipore, Billerica, MA) at the Laboratory for Clinical Biochemistry Research
(University of Vermont, Burlington, VT), as previously reported.^{25, 26} The coefficients of variation
for these assays ranged from 6 to 13%.

127 Dependent variables assessment

From a standard lipid panel, RC levels were estimated as non-HDL-C *minus* LDL-C. LDL-C was estimated using the Martin/Hopkins equation. This method estimates LDL-C using 1 of 174 different factors for the TG to VLDL-C ratio according to non-HDL-C and TG levels when TG levels are <400 mg/dL.²⁷ We additionally performed similar estimation when TG levels were 400-132 799 mg/dL using an expanded version of the Martin/Hopkins method that uses several more factors with increased accuracy.²⁸ Our group has previously shown that this estimation method for RC levels is more accurate than using the Friedewald equation.²⁹

135 Covariates

The covariates included in this study include the following demographic, behavioral and 136 ASCVD risk factors measured at the visit of the adipokine assessment: age, sex, race/ethnicity, 137 138 study site, education (<high school; high school or vocational school; college, graduate or 139 professional school), cigarette smoking status (current, former or never), physical activity (MET hrs/week of moderate or vigorous activity, continuous), BMI (in kg/m²), total cholesterol (mg/dL), 140 141 HDL-C (mg/dL), use of lipid lowering medications (yes/no), diabetes (defined as fasting blood sugar \geq 126 on non-fasting glucose \geq 200 mg/dl or medication use), and measures of abdominal 142 143 body composition (VAT and SAT) by CT. In exploratory models, we replaced BMI with VAT and 144 SAT measures from abdominal CTs from visits 2/3. We also explored new use of lipid lowering 145 medications during follow-up at visits 4, 5 and 6.

146 Statistical analysis

We described the baseline demographics and clinical characteristics of the study participants at the time of their adipokine level measurement, stratified by tertiles of each adipokine (adiponectin, leptin and resistin, separately). Continuous variables were expressed as mean and standard deviations (SD) and categorical variables as frequency and percentages. For our regression models, both RC and adipokine levels and their ratios were log-transformed given their non-normal distribution. The regression results were then exponentiated and shown as percent differences using the following formula: $(\epsilon^{\beta}-1)*100$.

Our primary outcome was RC levels (estimated as described above) assessed crosssectionally at visits 2 or 3. Our secondary outcome was the prospective change in RC levels from the time of measurement of adipokines (either visit 2 or 3) to Exam 6. We used standard lipid panels from visits 2, 3, 4, 5, and 6 to leverage all available lipid panels in mixed effects linear regression models.

159 We assessed the longitudinal change in RC levels associated with each of the adipokine 160 levels separately by using multivariable-adjusted linear mixed effects models allowing for random 161 variations in baseline RC levels and longitudinal slope for RC progression across participants. The 162 mixed effects model for longitudinal data leverages all available lipid panel (RC) information from 163 all participants, including those without follow-up measurements, to jointly model the level of RC 164 at baseline and RC change over time. In this mixed effect model, cross-sectional associations are 165 represented by coefficients of the adipokines, which estimate the difference in RC at baseline by 166 varying adipokine levels. Longitudinal associations are represented by coefficients of interactions 167 between adipokines and time since baseline, which estimate the rate of change in RC levels 168 associated with adipokines.

169	The linear regression models were progressively adjusted as follows: Model 1 - age, sex,
170	race/ethnicity, and study site; Model 2 - Model 1 + education, smoking status, and physical
171	activity; Model 3 – Model 2 + BMI; Model 4 – Model 3 + LDL-C; Model 5 – Model 4 + use of
172	lipid-lowering therapy; Model 6 – Model 5 + diabetes mellitus; Model 7 - Model 5 + subcutaneous
173	fat area, in cm2 (instead of BMI); Model 8 – Model 5 + visceral fat area, in cm2 (instead of BMI)
174	For sensitivity analyses, we evaluated interactions by sex, diabetes mellitus and obesity status
175	$(BMI \ge 30 \text{ vs} < 30 \text{ kg/m2}).$
176	
177	RESULTS
178	Study population
179	The mean age (SD) of the population was 64.5 (9.6) years, and about half of them were
180	women (52%). In terms of race/ethnicity, the majority of individuals were of White (39.8%),
181	followed by Hispanic (25.5%), Black (21.1%) and Chinese-Americans (13.6%). The mean (SD)
182	BMI of the population was 29.9 (5.0) kg/m2. The median (IQR) TG levels were 113 (77-161)
183	mg/dL, and the median (IQR) RC levels were 21.8 (16.9-27.8) mg/dL. The median (IQR) values
184	for adipokines were: adiponectin, 17.5 (11.9-26.4) ng/mL; leptin, 13.1 (5.6-28.2) ng/mL; and
185	resistin, 14.9 (11.9-18.8) ng/mL.
186	Baseline characteristics by adipokine levels
187	The baseline characteristics were estimated per tertiles of each adipokines separately to
188	more evenly distribute the population, and are shown in Table 1 (adiponectin), Table 2 (leptin),
189	and Table 3 (resistin).
190	Compared to lower tertiles of adiponectin, we observed significantly higher proportions
191	of females, White individuals and never smokers, but lower proportions of individuals with

192 diabetes mellitus (p < 0.05) in the highest tertile of adiponectin. In the highest tertile of 193 adiponectin, we also observed lower levels of both TG and RC, but higher levels of HDL-C. We did not observe significant differences in levels of BMI, TC and LDL-C across adiponectin 194 195 tertiles (Table 1). 196 Compared to lower tertiles of leptin, we observed significantly higher proportions of 197 females, Black and Hispanic individuals, and never smokers in the highest tertile of leptin. We 198 also observed higher proportions of diabetes mellitus, along with greater use of antihypertensive 199 and lipid-lowering medications with higher leptin. With regards to lipid parameters, we observed 200 higher levels of TG and RC in the highest compared to lower leptin tertiles. We found that those 201 in the highest leptin tertile had significantly higher BMI levels compared to lower tertiles 202 (p < 0.05). Contrarily, we did not find significant differences in TC and LDL-C across leptin 203 tertiles (Table 2). 204 Finally, we found significantly higher BMI levels in the highest compared to lower 205 tertiles of resistin, along with prevalence of diabetes mellitus and use of antihypertensive 206 medications (p<0.05). In the highest resistin tertile, the average TG level was higher and HDL-C

207 was lower, but we did not find any significant differences between lipid parameters, including

208 LDL-C and RC, across tertiles (Table 3).

209 Cross sectional association between adipokines and RC

The associations between adipokines and RC are shown graphically in the figures.
Figure 1 shows an inverse association between adiponectin and RC levels, whereas Figure 2
shows a direct association between leptin and RC. Levels of resistin appears to be equally
dispersed across levels of RC in Figure 3.

214	In our cross-sectional linear regression models, we observed that after adjustment for
215	demographic variables (Model 1), each 1-unit increment in adiponectin was associated with a
216	17.3% (14.8, 19.7) lower level of RC, whereas similar 1-unit increments in leptin and resistin
217	were associated with 7.3% (6.2, 9.4) and 6.2% (2.0, 10.5) higher RC levels (Table 4). In fully
218	adjusted models that included BMI, LDL-C and lipid-lowering therapy (Model 5), we observed
219	that for each 1-unit increment in adiponectin, RC levels were 14.4% (12.0, 16.8) lower.
220	Conversely, 1-unit increment changes in leptin and resistin were associated with higher RC
221	levels by 4.5% (2.3, 6.6) and 5.1% (1.2, 9.2), respectively. Similar results were observed in
222	models that included subcutaneous (Model 6) and visceral fat area (Model 7) instead of BMI
223	(Table 4). We did not find effect modification by sex, diabetes mellitus or obesity (p-value for
224	interaction >0.05).
225	Longitudinal association between adipokines and RC
226	Participants were followed for median (IQR) of 5 (4-8) years. In longitudinal analyses we
227	observed that for each 1-unit increment in baseline adiponectin, there was a 14.2% (12.0, 16.4)
228	reduction in RC levels over time after adjusting for demographic and cardiovascular risk factors

229 (Model 2). After further adjusting for other time-varying covariates such as BMI, LDL-C and

230 lipid-lowering therapy (Model 5), we observed a 11.6% (9.5, 13.6) reduction in RC over time.

We found a 6.3% (4.8, 7.8) increase in RC over time for each increase in 1-unit of leptin,
although this increase was only 1.6-1.8% after further adjusting for BMI, LDL-C, lipid-lowering

therapy, and diabetes (Model 4-6, **Table 5**). We did not find significant or clinically relevant

associations between resistin levels and longitudinal changes in RC (Table 5).

235

236 **DISCUSSION**

In this multiethnic cohort of individuals, we observed a significant inverse cross-sectional association between adiponectin and levels of RC, whereas we found a significant but less potent associations of leptin and resistin with levels of RC. In longitudinal analyses, we found that only baseline levels of adiponectin continued to have a strong independent inverse association with RC levels over time, whereas leptin had a more modest association and resistin was not associated with longitudinal change in RC levels.

243 The relationship between TG and ASCVD has been complex and historically difficult to 244 define. It has been shown that individuals with hypertriglyceridemia have increased rates of 245 secretion of TG overloaded very low-density lipoproteins, which then metabolize to small dense LDL particles, which are shown to be highly atherogenic.³⁰ On the other hand, many 246 247 epidemiologic studies showed a strong role for low HDL-C as a predictor of cardiovascular risk, 248 suggesting it may even be a better predictor than high TG. The association between TG and 249 ASCVD was shown to be attenuated after adjusting for HDL-C. However, TG and HDL-C have a strong inverse association,¹⁴ and it was unclear which of the two was really the culprit for 250 251 development of ASCVD. Over the past decade, multiple trials of HDL-C raising therapies failed to show a benefit with regards to risk;³¹⁻³³ further, genetic studies^{34, 35} have helped to confirm that 252 253 HDL-C is not a causal risk factor for ASCVD, but it may rather be a marker of high TG levels. 254 TGRL contain both triglycerides and cholesterol. However, the simplest measurement of 255 TGRL are serum TG and RC, both of which can be easily obtained from the standard lipid panel.³⁶ In order to cause atherosclerosis, TGRL need to enter into the arterial intimal space. 256 257 However, unlike cholesterol, TG can be degraded by most cells and do not accumulate in the 258 atherosclerotic plaque; for these reasons it has been considered that, pathophysiologically 259 speaking, TG could not be a promoter of atherosclerosis. Instead, it has been suggested that

260	serum/plasma levels of TG should be rather considered as a marker of high levels of cholesterol
261	within TGRL (i.e. RC). ³⁶ RC represents the concentration of all plasma cholesterol not found in
262	LDL and HDL; or in other words, in all TGRL. RC has been shown to be associated with events
263	by several observational studies. For instance, we showed that RC was associated with
264	progression of atheroma in a secondary prevention population, ¹⁶ as well as incident events
265	independent of LDL-C and apolipoprotein B (apoB) levels in a pooled cohort of individuals free
266	of ASCVD. ³⁷ Further, Mendelian randomization studies confirmed the causal role of RC in the
267	development of atherosclerosis. ¹⁴
268	To the best of our knowledge, this is the first study evaluating the association between

adipokines and remnant cholesterol. In our study we observed that out of the three adipokines 269 that we evaluated, only adiponectin continued to be significantly associated with RC in both 270 271 cross-sectional and longitudinal analyses with similar results between the two models. 272 Adiponectin is an adipocyte-specific hormone that has been classically shown to be reduced in 273 individuals with obesity, possibly due to several mechanisms including hypoxia, inflammation, and downregulation of β-adrenergic signaling.³⁸⁻⁴⁰ Adiponectin has several systemic insulin-274 sensitizing and anti-inflammatory properties,⁴¹⁻⁴³ given that its signaling leads to metabolic 275 276 health-promoting alterations such as decreased hepatic gluconeogenesis, increased fatty acid 277 oxidation in liver and skeletal muscle, protective effect on pancreatic β -cells, and increased glucose uptake in muscle.⁴¹ Adiponectin has also been shown to have anti-inflammatory 278 properties via its effects on TNF-alpha and C-reactive protein⁴⁴ with effects on formation of the 279 atherosclerotic plaque.^{45, 46} Thus, taken together, adiponectin is generally thought to be a 280 281 cardioprotective adipokine. Previous studies have shown that adiponectin levels are negatively 282 correlated with markers of TGRL metabolism, such as apoC-III, VLDL-triglycerides, apoB-48

levels. Interestingly, like previous studies,⁴⁷⁻⁴⁹ our findings were independent of presence of
diabetes mellitus at baseline. We did find an inverse association between adiponectin and levels
of RC; these findings could be explained by three mechanisms based on previous studies from
the literature. First, adiponectin may decrease accumulation of TG in skeletal muscle by
enhancing fatty acid oxidation;⁵⁰ second, adiponectin can stimulate lipoprotein lipase in the liver
and adipocytes;⁵¹ third, adiponectin may decrease the supply of nonesterified fatty acid to the
liver for gluconeogenesis which leads to decreased TG synthesis.⁵²

290 Leptin is an adipokine that is almost exclusively expressed in adipocytes; it has been 291 proposed that the most important physiologic role of leptin is via appetite suppression and 292 promoting energy expenditure through receptors in the central nervous system. Circulating leptin levels have been shown to correlate positively with adipose tissue mass,⁵³ as we observed in our 293 294 study. However, other physiologic roles of leptin are not well established or understood. For 295 instance, it has been also suggested that leptin signaling also occurs in pancreatic β -cells with 296 some in-vitro studies showing that leptin signaling inhibits insulin secretion and increases survival of β-cells.^{54, 55} However, these findings have not been confirmed with in-vivo studies: 297 298 mouse models with LEPR knockdown restricted to β -cells found no evidence of hyperinsulinemia or disturbed glucose hemostasis.⁵⁶ In a prior MESA analysis, leptin levels were 299 not found to be independently associated with ASCVD after accounting for BMI.⁵⁷ In our study, 300 301 we found an increasing prevalence of diabetes mellitus at higher leptin levels, which could be 302 due to greater adiposity as reflected by higher BMI. Higher levels of TG and RC in the highest 303 tertile of leptin could be due to the greater prevalence of diabetes mellitus rather than a direct 304 effect of leptin; indeed the association between leptin and longitudinal change in RC was rather 305 weak and probably not clinically relevant.

Resistin, an adipokine released by tissue-resident macrophages rather than adipocytes,
accelerates insulin resistance and the development of inflammatory metabolic diseases.
However, no specific receptor has been identified so far, so the mechanism of this adipokine is
not fully understood. We did not identify significant longitudinal associations between resistin
levels and TG and/or RC, for which we hypothesize that the metabolic effect of resistin may not
be related to TGRL.

312 Strengths and Limitations

313 Our study has several strengths. First, we used the definition of non-HDL-C minus 314 Martin/Hopkins LDL-C given its availability from the standard lipid panel at no extra cost and superiority when compared with RC extrapolated from Friedewald LDL-C.²⁹ This estimation 315 316 method has been used by most studies in the literature, and includes both atherogenic remnant 317 particles and large non-atherogenic particles such as large VLDL. Second, we were able to adjust 318 for other markers of adiposity, particularly VAT which has been proposed to be a more accurate 319 marker of abdominal obesity compared to waist circumference and BMI; furthermore, it has been proposed that visceral adiposity is the primary source of adipokines.⁵⁸ Third, three of the most 320 321 important and clinically relevant adipokines were included in this study, and they were measured 322 by standardized and reproducible methods. Fourth, we were able to obtain data from subsequent 323 visits after baseline in a time-varying fashion, such as BMI, LDL-C, age, smoking status and use 324 of lipid-lowering therapies. Fifth, we were able to perform mixed effect models to model RC 325 change over time, which has more statistical power than cross-sectional analysis. 326 Our study has some limitations. First, given the observational nature of the study design,

327 we cannot rule out the presence of residual confounding by unmeasured covariates. Second,

adipokines were only measured once (either visit 2 or 3), for which we were not able to evaluate

329	the association between change in adipokines over time and RC over time. It should be
330	considered that RLP can also induce proinflammatory cytokines released from adipocytes and
331	decreased adiponectin secretion by activating NF-kB and JNK pathways ⁵⁹ or induce
332	adipogenesis in an apoE-dependent manner ⁶⁰ leading to an increase in the amount of adipose
333	tissue. Therefore, it may not be possible to fully distinguish the direction of the association
334	between adipokines and RC. Third, the sample size of our study was relatively small for which
335	stratified analyses were not sufficiently powered to detect significant differences.
336	
337	Conclusion
337 338	Conclusion Lower adiponectin and higher leptin levels were associated with worse metabolic profile,
337 338 339	Conclusion Lower adiponectin and higher leptin levels were associated with worse metabolic profile, and associated with higher levels of remnant cholesterol independent of traditional risk factors
337 338 339 340	Conclusion Lower adiponectin and higher leptin levels were associated with worse metabolic profile, and associated with higher levels of remnant cholesterol independent of traditional risk factors including obesity markers. Additionally, adiponectin levels were significantly independently
337 338 339 340 341	Conclusion Lower adiponectin and higher leptin levels were associated with worse metabolic profile, and associated with higher levels of remnant cholesterol independent of traditional risk factors including obesity markers. Additionally, adiponectin levels were significantly independently inversely associated with changes in RC over time, whereas leptin levels were modestly
337 338 339 340 341 342	Conclusion Lower adiponectin and higher leptin levels were associated with worse metabolic profile, and associated with higher levels of remnant cholesterol independent of traditional risk factors including obesity markers. Additionally, adiponectin levels were significantly independently inversely associated with changes in RC over time, whereas leptin levels were modestly positively associated with longitudinal increase in RC. These findings might help explain the link
337 338 339 340 341 342 343	Conclusion Lower adiponectin and higher leptin levels were associated with worse metabolic profile, and associated with higher levels of remnant cholesterol independent of traditional risk factors including obesity markers. Additionally, adiponectin levels were significantly independently inversely associated with changes in RC over time, whereas leptin levels were modestly positively associated with longitudinal increase in RC. These findings might help explain the link between obesity and ASCVD pathogenesis.

345 **Disclosures:**

346	Unrelated to this work, Dr. Michos served as a consultant for Amgen, Amarin, AstraZeneca,
347	Bayer, Boehringer Ingelheim, Edwards Life Science, Esperion, Medtronic, Novartis, Novo
348	Nordisk, and Pfizer. She is a co-investigator on a grant funded by Merck. Outside of this work,
349	Dr. Martin reports consulting fees from Amgen, AstraZeneca, Bristol Myers Squibb, Dalcor,
350	Esperion, iHealth, Kaneka, NewAmsterdam, Novartis, Novo Nordisk, Sanofi, and 89bio. He is a
351	co-investigator on a grant funded by Merck. Dr. Martin is a coinventor on a patent application
352	filed by Johns Hopkins University for the Martin/Hopkins method of low-density lipoprotein
353	cholesterol and that patent application has since been abandoned to enable use without
354	intellectual property restrictions. None of the other authors report any conflicts of interest.
355	Sources of Funding:
356	Dr. Quispe is supported by an NIH T32 training grant (5T32HL007227). Drs. Michos is
357	supported by the Amato Fund for Women's Cardiovascular Health at Johns Hopkins. The MESA
358	study is supported by contracts HHSN268201500003I, N01-HC-95159, N01-HC-95160, N01-
359	HC-95161, N01-HC-95162, N01-HC-95163, N01-HC-95164, N01-HC-95165, N01-HC-95166,
360	N01-HC-95167, N01-HC-95168 and N01-HC-95169 from the NIH/NHLBI, by grants UL1-TR-
361	000040, UL1-TR-001079, and UL1-TR-001420 from NCATS. The ancillary data used in this
362	analysis were funded by R01 HL088451. Drs. Ndumele and Michos are additionally supported
363	for this work by an American Heart Association Strategic Focused Research Network Grant
364	20SFRN35120152.

365 Acknowledgements

- 366 The authors thank the other investigators, the staff, and the MESA participants for their valuable
- 367 contributions. A full list of participating MESA investigators and institutions can be found at
- 368 http://www.mesa-nhlbi.org.

370 REFERENCES

- 1. Fliotsos M, Zhao D, Rao VN, Ndumele CE, Guallar E, Burke GL, Vaidya D, Delaney
- 372 JCA and Michos ED. Body Mass Index From Early-, Mid-, and Older-Adulthood and Risk of
- 373 Heart Failure and Atherosclerotic Cardiovascular Disease: MESA. J Am Heart Assoc.
- **374** 2018;7:e009599.
- 2. Rao VN, Zhao D, Allison MA, Guallar E, Sharma K, Criqui MH, Cushman M,
- 376 Blumenthal RS and Michos ED. Adiposity and Incident Heart Failure and its Subtypes: MESA
- 377 (Multi-Ethnic Study of Atherosclerosis). JACC Heart Fail. 2018;6:999-1007.
- 378 3. Ndumele CE, Matsushita K, Lazo M, Bello N, Blumenthal RS, Gerstenblith G, Nambi V,
- 379 Ballantyne CM, Solomon SD, Selvin E, Folsom AR and Coresh J. Obesity and Subtypes of
- 380 Incident Cardiovascular Disease. J Am Heart Assoc. 2016;5.
- 381 4. Ward ZJ, Bleich SN, Cradock AL, Barrett JL, Giles CM, Flax C, Long MW and
- 382 Gortmaker SL. Projected U.S. State-Level Prevalence of Adult Obesity and Severe Obesity. N
- 383 *Engl J Med.* 2019;381:2440-2450.
- 384 5. Mandviwala T, Khalid U and Deswal A. Obesity and Cardiovascular Disease: a Risk
 385 Factor or a Risk Marker? *Curr Atheroscler Rep.* 2016;18:21.
- 386 6. Quispe R, Martin SS and Jones SR. Triglycerides to high-density lipoprotein-cholesterol
- ratio, glycemic control and cardiovascular risk in obese patients with type 2 diabetes. *Curr Opin Endocrinol Diabetes Obes*. 2016;23:150-6.
- 389 7. Davidson MH. Triglyceride-rich lipoprotein cholesterol (TRL-C): the ugly stepsister of
 390 LDL-C. *Eur Heart J.* 2018;39:620-622.
- 8. Boren J and Packard CJ. Keeping remnants in perspective. *Eur Heart J*. 2021.

- **392** 9. Laufs U, Parhofer KG, Ginsberg HN and Hegele RA. Clinical review on triglycerides.
- *Eur Heart J.* 2020;41:99-109c.
- 10. Chapman MJ, Ginsberg HN, Amarenco P, Andreotti F, Boren J, Catapano AL, Descamps
- 395 OS, Fisher E, Kovanen PT, Kuivenhoven JA, Lesnik P, Masana L, Nordestgaard BG, Ray KK,
- 396 Reiner Z, Taskinen MR, Tokgozoglu L, Tybjaerg-Hansen A, Watts GF and European
- 397 Atherosclerosis Society Consensus P. Triglyceride-rich lipoproteins and high-density lipoprotein
- 398 cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for
- 399 management. *Eur Heart J.* 2011;32:1345-61.
- 400 11. Proctor SD, Vine DF and Mamo JC. Arterial retention of apolipoprotein B(48)- and
- 401 B(100)-containing lipoproteins in atherogenesis. *Curr Opin Lipidol*. 2002;13:461-70.
- 402 12. Quispe R, Manalac RJ, Faridi KF, Blaha MJ, Toth PP, Kulkarni KR, Nasir K, Virani SS,
- 403 Banach M, Blumenthal RS, Martin SS and Jones SR. Relationship of the triglyceride to high-
- 404 density lipoprotein cholesterol (TG/HDL-C) ratio to the remainder of the lipid profile: The Very
- 405 Large Database of Lipids-4 (VLDL-4) study. *Atherosclerosis*. 2015;242:243-50.
- 406 13. Varbo A, Benn M, Tybjaerg-Hansen A and Nordestgaard BG. Elevated remnant
- 407 cholesterol causes both low-grade inflammation and ischemic heart disease, whereas elevated
- 408 low-density lipoprotein cholesterol causes ischemic heart disease without inflammation.
- 409 *Circulation*. 2013;128:1298-309.
- 410 14. Varbo A, Benn M, Tybjaerg-Hansen A, Jorgensen AB, Frikke-Schmidt R and
- 411 Nordestgaard BG. Remnant cholesterol as a causal risk factor for ischemic heart disease. J Am
- 412 *Coll Cardiol*. 2013;61:427-436.
- 413 15. Quispe R, Martin SS, Michos ED, Lamba I, Blumenthal RS, Saeed A, Lima JAC, Puri R,
- 414 Nomura SO, Tsai MY, Wilkins JT, Ballantyne CM, Nicholls SJ, Jones SR and Elshazly MB.

- 415 Remnant cholesterol predicts cardiovascular disease beyond LDL and ApoB: a primary
- 416 prevention study. *Eur Heart J.* 2021.
- 417 16. Elshazly MB, Mani P, Nissen S, Brennan DM, Clark D, Martin S, Jones SR, Quispe R,
- 418 Donnellan E, Nicholls SJ and Puri R. Remnant cholesterol, coronary atheroma progression and
- 419 clinical events in statin-treated patients with coronary artery disease. Eur J Prev Cardiol.
- **420** 2020;27:1091-1100.
- 421 17. D'Souza A M, Neumann UH, Glavas MM and Kieffer TJ. The glucoregulatory actions of
 422 leptin. *Mol Metab.* 2017;6:1052-1065.
- 423 18. Hsu WY, Chao YW, Tsai YL, Lien CC, Chang CF, Deng MC, Ho LT, Kwok CF and
- 424 Juan CC. Resistin induces monocyte-endothelial cell adhesion by increasing ICAM-1 and
- 425 VCAM-1 expression in endothelial cells via p38MAPK-dependent pathway. *J Cell Physiol*.
- **426** 2011;226:2181-8.
- 427 19. Hansen D, Dendale P, Beelen M, Jonkers RA, Mullens A, Corluy L, Meeusen R and van
- 428 Loon LJ. Plasma adipokine and inflammatory marker concentrations are altered in obese, as
- 429 opposed to non-obese, type 2 diabetes patients. *Eur J Appl Physiol*. 2010;109:397-404.
- 430 20. Li S, Shin HJ, Ding EL and van Dam RM. Adiponectin levels and risk of type 2 diabetes:
- 431 a systematic review and meta-analysis. *Jama*. 2009;302:179-88.
- 432 21. Arita Y, Kihara S, Ouchi N, Maeda K, Kuriyama H, Okamoto Y, Kumada M, Hotta K,
- 433 Nishida M, Takahashi M, Nakamura T, Shimomura I, Muraguchi M, Ohmoto Y, Funahashi T
- 434 and Matsuzawa Y. Adipocyte-derived plasma protein adiponectin acts as a platelet-derived
- 435 growth factor-BB-binding protein and regulates growth factor-induced common postreceptor
- 436 signal in vascular smooth muscle cell. *Circulation*. 2002;105:2893-8.

- 437 22. Sweeney T, Ogunmoroti O, Ndumele CE, Zhao D, Varma B, Allison MA, Budoff MJ,
- 438 Fashanu OE, Sharma A, Bertoni AG and Michos ED. Associations of adipokine levels with the
- 439 prevalence and extent of valvular and thoracic aortic calcification: The Multi-Ethnic Study of
- 440 Atherosclerosis (MESA). *Atherosclerosis*. 2021;338:15-22.
- 441 23. Varma B, Ogunmoroti O, Ndumele CE, Di Z, Szklo M, Sweeney T, Allison MA, Budoff
- 442 MJ, Subramanya V, Bertoni AG and Michos ED. Higher Leptin Levels Are Associated with
- 443 Coronary Artery Calcium Progression: the Multi-Ethnic Study of Atherosclerosis (MESA).
- 444 *Diabetes Epidemiology and Management*. 2021:100047.
- 445 24. Broni EK, Ogunmoroti O, Quispe R, Sweeney T, Varma B, Fashanu OE, Lutsey PL,
- 446 Allison M, Szklo M, Ndumele CE and Michos ED. Adipokines and Incident Venous
- 447 Thromboembolism: The Multi-Ethnic Study of Atherosclerosis. *Journal of Thrombosis and*448 *Haemostasis*. 2022.
- 449 25. Vella CA, Allison MA, Cushman M, Jenny NS, Miles MP, Larsen B, Lakoski SG,
- 450 Michos ED and Blaha MJ. Physical Activity and Adiposity-related Inflammation: The MESA.
- 451 *Med Sci Sports Exerc.* 2017;49:915-921.
- 452 26. Rasmussen-Torvik LJ, Wassel CL, Ding J, Carr J, Cushman M, Jenny N and Allison MA.
- 453 Associations of body mass index and insulin resistance with leptin, adiponectin, and the leptin-
- 454 to-adiponectin ratio across ethnic groups: the Multi-Ethnic Study of Atherosclerosis (MESA).
- 455 Ann Epidemiol. 2012;22:705-9.
- 456 27. Martin SS, Blaha MJ, Elshazly MB, Toth PP, Kwiterovich PO, Blumenthal RS and Jones
- 457 SR. Comparison of a novel method vs the Friedewald equation for estimating low-density
- 458 lipoprotein cholesterol levels from the standard lipid profile. *JAMA*. 2013;310:2061-8.

459	28.	Saija A. Park	J. Sathivakumar V	. Varghese B	. Pallazola VA	A. Marvel FA	. Kulkarni K
.00	- 0.			, angliebe D	, I WIIWEDDIW / I	IN ITION TO I I I I	4 I K 00 I I K 00 I I I I I

- 460 Muthukumar A, Joshi PH, Gianos E, Hirsh B, Mintz G, Goldberg A, Morris PB, Sharma G,
- 461 Blumenthal RS, Michos ED, Post WS, Elshazly MB, Jones SR and Martin SS. Comparison of
- 462 Methods to Estimate Low-Density Lipoprotein Cholesterol in Patients With High Triglyceride
- 463 Levels. JAMA Netw Open. 2021;4:e2128817.
- 464 29. Faridi KF, Quispe R, Martin SS, Hendrani AD, Joshi PH, Brinton EA, Cruz DE, Banach
- 465 M, Toth PP, Kulkarni K and Jones SR. Comparing different assessments of remnant lipoprotein
- 466 cholesterol: The very large database of lipids. *J Clin Lipidol*. 2019;13:634-644.
- 467 30. Watts GF and Chan DC. Atherogenic Dyslipoproteinemia and Management of ASCVD:
- 468 Will New Indices Untie the Gordian Knot? *J Am Coll Cardiol*. 2020;75:2136-2139.
- 469 31. Barter PJ, Caulfield M, Eriksson M, Grundy SM, Kastelein JJ, Komajda M, Lopez-
- 470 Sendon J, Mosca L, Tardif JC, Waters DD, Shear CL, Revkin JH, Buhr KA, Fisher MR, Tall
- 471 AR, Brewer B and Investigators I. Effects of torcetrapib in patients at high risk for coronary
- 472 events. *The New England journal of medicine*. 2007;357:2109-22.
- 473 32. Schwartz GG, Olsson AG, Abt M, Ballantyne CM, Barter PJ, Brumm J, Chaitman BR,
- 474 Holme IM, Kallend D, Leiter LA, Leitersdorf E, McMurray JJ, Mundl H, Nicholls SJ, Shah PK,
- 475 Tardif JC, Wright RS and dal OI. Effects of dalcetrapib in patients with a recent acute coronary
- 476 syndrome. *The New England journal of medicine*. 2012;367:2089-99.
- 477 33. Investigators A-H, Boden WE, Probstfield JL, Anderson T, Chaitman BR, Desvignes-
- 478 Nickens P, Koprowicz K, McBride R, Teo K and Weintraub W. Niacin in patients with low HDL
- 479 cholesterol levels receiving intensive statin therapy. *N Engl J Med.* 2011;365:2255-67.
- 480 34. Agerholm-Larsen B, Tybjaerg-Hansen A, Schnohr P, Steffensen R and Nordestgaard BG.
- 481 Common cholesteryl ester transfer protein mutations, decreased HDL cholesterol, and possible

decreased risk of ischemic heart disease: The Copenhagen City Heart Study. *Circulation*.
2000;102:2197-203.

484 35. Agerholm-Larsen B, Nordestgaard BG, Steffensen R, Jensen G and Tybjaerg-Hansen A.

485 Elevated HDL cholesterol is a risk factor for ischemic heart disease in white women when

486 caused by a common mutation in the cholesteryl ester transfer protein gene. *Circulation*.

487 2000;101:1907-12.

488 36. Nordestgaard BG. Triglyceride-Rich Lipoproteins and Atherosclerotic Cardiovascular

489 Disease: New Insights From Epidemiology, Genetics, and Biology. *Circ Res.* 2016;118:547-63.

490 37. Quispe R, Martin SS, Michos ED, Lamba I, Blumenthal RS, Saeed A, Lima J, Puri R,

491 Nomura S, Tsai M, Wilkins J, Ballantyne CM, Nicholls S, Jones SR and Elshazly MB. Remnant

492 cholesterol predicts cardiovascular disease beyond LDL and ApoB: a primary prevention study.

Eur Heart J. 2021;42:4324-4332.

494 38. Komai AM, Musovic S, Peris E, Alrifaiy A, El Hachmane MF, Johansson M, Wernstedt

495 Asterholm I and Olofsson CS. White Adipocyte Adiponectin Exocytosis Is Stimulated via beta3-

496 Adrenergic Signaling and Activation of Epac1: Catecholamine Resistance in Obesity and Type 2

497 Diabetes. *Diabetes*. 2016;65:3301-3313.

498 39. Kikai M, Yamada H, Wakana N, Terada K, Yamamoto K, Wada N, Motoyama S, Saburi

499 M, Sugimoto T, Irie D, Kato T, Kawahito H, Ogata T and Matoba S. Adrenergic receptor-

500 mediated activation of FGF-21-adiponectin axis exerts atheroprotective effects in brown adipose

tissue-transplanted apoE(-/-) mice. *Biochem Biophys Res Commun.* 2018;497:1097-1103.

502 40. Trayhurn P. Hypoxia and adipose tissue function and dysfunction in obesity. *Physiol Rev.*503 2013;93:1-21.

- 504 41. Fang H and Judd RL. Adiponectin Regulation and Function. *Compr Physiol*.
- 505 2018;8:1031-1063.
- 506 42. Maeda N, Shimomura I, Kishida K, Nishizawa H, Matsuda M, Nagaretani H, Furuyama
- 507 N, Kondo H, Takahashi M, Arita Y, Komuro R, Ouchi N, Kihara S, Tochino Y, Okutomi K,
- 508 Horie M, Takeda S, Aoyama T, Funahashi T and Matsuzawa Y. Diet-induced insulin resistance
- in mice lacking adiponectin/ACRP30. *Nat Med.* 2002;8:731-7.
- 510 43. Kim JY, van de Wall E, Laplante M, Azzara A, Trujillo ME, Hofmann SM, Schraw T,
- 511 Durand JL, Li H, Li G, Jelicks LA, Mehler MF, Hui DY, Deshaies Y, Shulman GI, Schwartz GJ
- and Scherer PE. Obesity-associated improvements in metabolic profile through expansion of
- 513 adipose tissue. J Clin Invest. 2007;117:2621-37.
- 514 44. Whitehead JP, Richards AA, Hickman IJ, Macdonald GA and Prins JB. Adiponectin--a
- 515 key adipokine in the metabolic syndrome. *Diabetes Obes Metab.* 2006;8:264-80.
- 516 45. Kadowaki T and Yamauchi T. Adiponectin and adiponectin receptors. *Endocr Rev.*517 2005;26:439-51.
- 518 46. Hopkins TA, Ouchi N, Shibata R and Walsh K. Adiponectin actions in the cardiovascular
 519 system. *Cardiovasc Res.* 2007;74:11-8.
- 520 47. Chan DC, Watts GF, Ng TW, Uchida Y, Sakai N, Yamashita S and Barrett PH.
- 521 Adiponectin and other adipocytokines as predictors of markers of triglyceride-rich lipoprotein
- 522 metabolism. *Clin Chem.* 2005;51:578-85.
- 523 48. Kazumi T, Kawaguchi A, Hirano T and Yoshino G. Serum adiponectin is associated with
- 524 high-density lipoprotein cholesterol, triglycerides, and low-density lipoprotein particle size in
- 525 young healthy men. *Metabolism*. 2004;53:589-93.

- 526 49. Komatsu M, Ohfusa H, Aizawa T and Hashizume K. Adiponectin inversely correlates
- 527 with high sensitive C-reactive protein and triglycerides, but not with insulin sensitivity, in
- 528 apparently healthy Japanese men. *Endocr J.* 2007;54:553-8.
- 529 50. Yamauchi T, Kamon J, Minokoshi Y, Ito Y, Waki H, Uchida S, Yamashita S, Noda M,
- 530 Kita S, Ueki K, Eto K, Akanuma Y, Froguel P, Foufelle F, Ferre P, Carling D, Kimura S, Nagai
- 531 R, Kahn BB and Kadowaki T. Adiponectin stimulates glucose utilization and fatty-acid oxidation
- 532 by activating AMP-activated protein kinase. *Nat Med.* 2002;8:1288-95.
- 533 51. Combs TP, Pajvani UB, Berg AH, Lin Y, Jelicks LA, Laplante M, Nawrocki AR, Rajala
- 534 MW, Parlow AF, Cheeseboro L, Ding YY, Russell RG, Lindemann D, Hartley A, Baker GR,
- 535 Obici S, Deshaies Y, Ludgate M, Rossetti L and Scherer PE. A transgenic mouse with a deletion
- 536 in the collagenous domain of adiponectin displays elevated circulating adiponectin and improved
- 537 insulin sensitivity. *Endocrinology*. 2004;145:367-83.
- 538 52. Yamauchi T, Kamon J, Waki H, Terauchi Y, Kubota N, Hara K, Mori Y, Ide T,
- 539 Murakami K, Tsuboyama-Kasaoka N, Ezaki O, Akanuma Y, Gavrilova O, Vinson C, Reitman
- 540 ML, Kagechika H, Shudo K, Yoda M, Nakano Y, Tobe K, Nagai R, Kimura S, Tomita M,
- 541 Froguel P and Kadowaki T. The fat-derived hormone adiponectin reverses insulin resistance
- sociated with both lipoatrophy and obesity. *Nat Med.* 2001;7:941-6.
- 543 53. Boden G, Chen X, Mozzoli M and Ryan I. Effect of fasting on serum leptin in normal
 544 human subjects. *J Clin Endocrinol Metab.* 1996;81:3419-23.
- 545 54. Wu Y, Fortin DA, Cochrane VA, Chen PC and Shyng SL. NMDA receptors mediate
- 546 leptin signaling and regulate potassium channel trafficking in pancreatic beta-cells. *J Biol Chem.*
- 547 2017;292:15512-15524.

- 548 55. Dunmore SJ and Brown JE. The role of adipokines in beta-cell failure of type 2 diabetes.
 549 *J Endocrinol.* 2013;216:T37-45.
- 550 56. Soedling H, Hodson DJ, Adrianssens AE, Gribble FM, Reimann F, Trapp S and Rutter
- 551 GA. Limited impact on glucose homeostasis of leptin receptor deletion from insulin- or
- proglucagon-expressing cells. *Mol Metab*. 2015;4:619-30.
- 553 57. Martin SS, Blaha MJ, Muse ED, Qasim AN, Reilly MP, Blumenthal RS, Nasir K, Criqui
- 554 MH, McClelland RL, Hughes-Austin JM and Allison MA. Leptin and incident cardiovascular
- disease: the Multi-ethnic Study of Atherosclerosis (MESA). *Atherosclerosis*. 2015;239:67-72.
- 556 58. Dutheil F, Gordon BA, Naughton G, Crendal E, Courteix D, Chaplais E, Thivel D, Lac G
- and Benson AC. Cardiovascular risk of adipokines: a review. J Int Med Res. 2018;46:2082-2095.
- 558 59. Barnes PJ and Karin M. Nuclear factor-kappaB: a pivotal transcription factor in chronic
- inflammatory diseases. *N Engl J Med.* 1997;336:1066-71.
- 560 60. Chiba T, Nakazawa T, Yui K, Kaneko E and Shimokado K. VLDL induces adipocyte
- differentiation in ApoE-dependent manner. Arterioscler Thromb Vasc Biol. 2003;23:1423-9.

562

TABLES

564

565

566

567	
-----	--

Table 1 – Baseline characteristics by tertiles of adiponectin (n=1,791)

	Lowest Tertile	Second Tertile	Highest Tertile	p-value
Age, years	62.2 ± 9.2	64.5 ± 9.5	66.8 ± 9.5	0.591
Female	210 (35.2)	300 (50.3)	421 (70.5)	<0.001
Race/ethnicity				<0.001
White	158 (26.5)	225 (37.7)	330 (55.3)	
Chinese-American	119 (19.9)	71 (11.9)	53 (8.9)	
Black	171 (28.6)	115 (19.3)	92 (15.4)	
Hispanic	149 (25.0)	186 (31.2)	122 (20.4)	
Smoking status				0.023
Never	265 (44.4)	272 (45.6)	302 (50.6)	
Former	246 (41.2)	258 (43.2)	242 (40.5)	
Current	86 (14.4)	67 (11.2)	53 (8.9)	
BMI, kg/m2	29.0 ± 5.0	28.2 ± 4.9	26.4 ± 4.8	0.523
SBP, mmHg	124.2 ± 20.5	123.6 ± 19.9	123.3 ± 22.1	0.031
Triglycerides,	130	117	89	<0.001
mg/dl	(93-180)	(81-164)	(65-136)	
RC, mg/dl	23.6 (19.1-30.2)	22.3 (17.3-28.8)	18.8 (15-24.9)	<0.001
Total Cholesterol, mg/dl	185.6 ± 36.0	191.0 ± 34.6	193.5 ± 35.4	0.632
LDL-C, mg/dl	115.1 ± 31.1	115.5 ± 30.2	112.5 ± 30.7	0.764
HDL-C, mg/dL	44.8 ± 11.2	51.3 ± 13.2	60.0 ± 16.8	<0.001
Diabetes	112 (18.8)	72 (12.1)	54 (9.1)	<0.001
Antihypertensive medications	251 (43.3)	244 (42)	246 (42.3)	0.901
Lipid-lowering medications	147 (25.3)	152 (26.2)	133 (22.9)	0.406

Values are shown using mean \pm SD for normal and median (25th-75th percentile) for not-normal 568 continuous variables, and n(%) for categorical variables.

569

Comparison was made using chi-square (categorical), t-test (normal) or Kruskal-Wallis (not-570

normal). **Bold** values are statistically significant (p<0.05) 571

BMI: body mass index, SBP: systolic blood pressure, RC: remnant cholesterol; LDL-C: low-572

573 density lipoprotein cholesterol, HDL-C: high-density lipoprotein cholesterol

574 Table 2 – Baseline characteristics by tertiles of leptin (n=1,791)

575

	First Tertile	Second Tertile	Third Tertile	p-value
Age, years	64.3 ± 9.9	64.3 ± 9.9	65.0 ± 9.2	0.177
Female	125 (20.9)	295 (49.4)	511 (85.6)	<0.001
Race/ethnicity				<0.001
White	266 (44.6)	254 (42.6)	193 (32.3)	
Chinese-American	126 (21.1)	82 (13.7)	35 (5.9)	
Black	76 (12.7)	110 (18.4)	192 (32.2)	
Hispanic	129 (21.6)	151 (25.3)	177 (29.6)	
Smoking status				<0.001
Never	231 (38.7)	298 (49.9)	310 (51.9)	
Former	280 (46.9)	235 (39.4)	231 (38.7)	
Current	86 (14.4)	64 (10.7)	56 (9.4)	
BMI, kg/m2	24.8 ± 3.2	$\textbf{27.2} \pm \textbf{3.6}$	31.5 ± 5.4	<0.001
SBP, mmHg	120.0 ± 19.7	123.1 ± 20.0	127.9 ± 22.0	0.013
Triglycerides,	100	118	121	<0.001
mg/dl	(69-141)	(83-165)	(83-177)	
PC mg/dl	20	22.4	22.8	<0.001
KC, ing/ui	(15.7-25.4)	(17.4-28.3)	(17.8-30)	
Total Cholesterol, mg/dl	185.5 ± 33.8	190.2 ± 36.0	194.4 ± 36.1	0.204
LDL-C, mg/dl	111.7 ± 29.2	114.4 ± 31.2	117.1 ± 31.4	0.154
HDL-C, mg/dL	51.8 ± 16.2	51.7 ± 15.7	52.6 ± 13.8	<0.001
Diabetes	64 (10.7)	80 (13.4)	94 (15.8)	0.037
Antihypertensive medications	186 (31.9)	246 (42.3)	309 (53.7)	<0.001
Lipid-lowering medications	115 (19.7)	164 (28.2)	153 (26.5)	0.002

576 Values are shown using mean ±SD for normal and median (25th-75th percentile) for not-normal
 577 continuous variables, and n(%) for categorical variables.

578 Comparison was made using chi-square (categorical), t-test (normal) or Kruskal-Wallis (not-

579 normal). **Bold** values are statistically significant (p<0.05)

582 Table 3 – Baseline characteristics by tertiles of resistin (n=1,791)

583

	First Tertile	Second Tertile	Third Tertile	p-value
Age, years	62.8 ± 9.0	64.0 ± 9.5	66.8 ± 9.7	0.139
Female	307 (51.4)	292 (48.9)	332 (55.6)	0.065
Race/ethnicity		· · · · ·		<0.001
White	209 (35.0)	278 (46.6)	226 (37.9)	
Chinese-American	105 (17.6)	64 (10.7)	74 (12.4)	
Black	122 (20.4)	103 (17.3)	153 (25.6)	
Hispanic	161 (27.0)	152 (25.5)	144 (24.1)	
Smoking status				0.068
Never	298 (49.9)	263 (44.1)	278 (46.6)	
Former	242 (40.5)	249 (41.7)	255 (42.7)	
Current	57 (9.6)	85 (14.2)	64 (10.7)	
BMI, kg/m2	27.1 ± 4.7	28.1 ± 4.8	28.4 ± 5.4	0.002
SBP, mmHg	122.3 ± 20.4	122.1 ± 20.5	126.6 ± 21.3	0.550
Triglycerides, mg/dl	109 (76-149)	113 (76-164)	117 (80-171)	0.0371
RC, mg/dl	21.4 (16.6-26.3)	21.9 (16.7-28)	22 (17.3-28.9)	0.1222
Total Cholesterol, mg/dl	194.3 ± 35.8	188.4 ± 33.8	187.4 ± 36.6	0.144
LDL-C, mg/dl	117.2 ± 31.1	112.7 ± 30.1	113.2 ± 30.7	0.762
HDL-C, mg/dL	54.1 ± 16.3	52.0 ± 14.9	50.1 ± 14.2	0.003
Diabetes	63 (10.6)	75 (12.6)	100 (16.8)	0.006
Antihypertensive medications	210 (36.3)	238 (40.8)	293 (50.6)	<0.001
Lipid-lowering medications	141 (24.4)	156 (26.7)	135 (23.3)	0.388

Values are shown using mean \pm SD for normal and median (25th-75th percentile) for not-normal continuous variables, and n(%) for categorical variables.

586 Comparison was made using chi-square (categorical), t-test (normal) or Kruskal-Wallis (not-

587 normal). **Bold** values are statistically significant (p<0.05)

589	Table 4. Linear	regression	models for	associations	between	baseline ad	lipokines	and levels

590 591

	Model 1	Model 2	Model 3	Model 4	Model 5	Model 6	Model 7	Model 8
	-17.2	-17.1	-15.4	-15.0	-14.6	-14.6	-13.6	-10.2
Adiponectin	(-19.6, -	(-19.5, -	(-17.9, -	(-17.3, -	(-16.8, -	(-16.9,	(-16.0, -	(-12.5, -
	14.6)	14.6)	12.8)	12.6)	12.0)	-12.2)	11.1)	7.8)
	7.7 (5 9 9 6)	7.9 (6.0, 9.7)	5.1 (2.8, 7.5)	4.8 (2.7, 7.0)	4.5 (2.3, 6.6)	4.8	2.6 (0.5, 4.6)	2.3
Leptin						(2.7,		(1.0,
	(3.7, 7.0)					7.0)		3.6)
	6.0	5.6	3.6	4.4	5.1	4.0	3.6	3.4
Resistin	(1.6,	(1.2,	(-0.6,	(0.5, 8.4)	(1.2, 9.2)	(0.2,	(-0.7, 8.1)	(-0.3,
	10.5)	10.1)	8.0)			8.1)		7.2)

592 RC and adipokines levels were log-transformed. Results shown are shown as percent differences

593 [$(\epsilon^{\beta}-1)^*100$]. **Bold** values are statistically significant (p<0.05)

594 Model 1 - age, sex, race/ethnicity, and study site.

595 Model 2 – Model 1 + education, smoking status, and physical activity

596 Model 3 - Model 2 + BMI

of RC (n=1,791)

597 Model 4 - Model 3 + LDL-C

598 Model 5 – Model 4 + use of lipid-lowering therapy

599 Model 6 – Model 5 + diabetes mellitus

600 Model 7 - Model 6 + subcutaneous fat area, in cm^2 (instead of BMI)

601 Model 8 – Model 6 + visceral fat area, in cm^2 (instead of BMI)

603 Table 5. Mixed-model (longitudinal) analyses for associations between baseline adipokines

604 605

	Model	Model	Model	Model	Model	Model	Model 7	Model
	1	2	3	4	5	6		8
	-14.1	-14.2	-12.0	-12.1	-11.9	-11.6	-12.7 (-	-9.9 (-
Adiponectin	(-16.3,	(-16.4,	(-14.2,	(-14.1,	(-13.9,	(-13.6,	14.9, -	11.9, -
	-11.9)	-12.0)	-9.7)	-10.1)	-9.8)	-9.5)	10.4)	7.9)
	6.4	6.5	1.5	2.0	1.9	1.8	6.6 (4.5,	0.2 (-
Leptin	(4.8,	(4.9,	(-0.2,	(0.4,	(0.3,	(0.2,	8.6)	1.3, 1.7)
	8.0)	8.1)	3.3)	3.6)	3.5)	3.4)		
	4.5	4.1	1.8	3.0	3.2	2.8	4.0 (0.3,	3.6 (0.5,
Resistin	(0.7,	(0.4,	(-1.8,	(-0.2,	(-0.1,	(-0.4,	7.8)	6.8)
	8.3)	7.9)	5.5)	6.4)	6.5)	6.2)	,	,

606 RC and adipokines levels were log-transformed. Results shown are shown as percent differences

- 607 [(ϵ^{β} -1)*100]. **Bold** values are statistically significant (p<0.05)
- 608 Model 1 age, sex, race/ethnicity, and study site.
- 609 Model 2 Model 1 + education, smoking status, and physical activity
- 610 Model 3 Model 2 + BMI

and levels of RC

- $611 \qquad Model 4 Model 3 + LDL-C$
- 612 Model 5 Model 4 + use of lipid-lowering therapy
- 613 Model 6 Model 5 + diabetes mellitus
- 614 Model 7 Model 6 + subcutaneous fat area, in cm^2 (instead of BMI)
- 615 Model 8 Model 6 + visceral fat area, in cm² (instead of BMI)
- 616
- 617 Time-varying variables were age, smoking status, BMI, LDL-C and use of lipid-lowering therapy
- 618
- 619

FIGURES

Figure 1. Adiponectin vs. RC levels (log-transformed). Regression line with 95% CI is displayed.





Figure 2. Leptin vs. RC levels (log-transformed). Regression line with 95% CI is displayed.



